Skip to main content
INO
NASDAQ Life Sciences

Inovio Flags $36.7M in Preliminary Q2 Cash as Liquidity Fears Mount

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.825
Mkt Cap
$85.564M
52W Low
$0.95
52W High
$2.979
52W Position info
13% below low
Off High info
72% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

INO is trading near its 52-week low of $0.95 (13% below the low).

Summary

Inovio disclosed a preliminary Q2 2026 cash balance of $36.7 million, a key liquidity metric for the struggling biotech. The update arrives alongside a concurrent public offering, highlighting the company's urgent need for capital.


Key Events · Earnings and Guidance · INO

  • Preliminary Q2 Cash Balance

    Based on preliminary unaudited figures, Inovio estimates cash and cash equivalents of approximately $36.7 million as of June 30, 2026.

  • Liquidity Context

    The cash balance is disclosed against a backdrop of severe liquidity concerns, a recent $300 million shelf registration, and a concurrent public offering announced today.

  • Financial Reporting Caveat

    The estimate is subject to completion of quarter-end closing procedures and has not been reviewed by the company's auditor, Ernst & Young LLP.


Analysis · INO · Life Sciences

A preliminary cash balance of $36.7 million as of June 30, 2026, was disclosed by Inovio, a critical update given the company's severe liquidity issues and recent $300 million shelf registration. While the cash position offers some runway, it remains precarious for a pre-revenue biotech facing ongoing FDA skepticism and securities lawsuits. The disclosure coincides with a concurrent public offering, signaling an active push to raise capital and extend the runway.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, INO was trading at $0.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $85.6M. The 52-week trading range was $0.95 to $2.98. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

INO - Latest Insights

INO
Nov 10, 2026, 4:05 PM EST
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.46
Real-time Price: $1.42 info
Change: -$0.040 (-3%) info
Market Cap: $265.039M info
INO
Nov 10, 2026, 4:01 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.47
Real-time Price: $1.42 info
Change: -$0.050 (-3%) info
Market Cap: $265.039M info
INO
Nov 09, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.37
Real-time Price: $1.42 info
Change: +$0.050 (+4%) info
Market Cap: $265.039M info
INO
Nov 06, 2026, 4:30 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $1.21
Real-time Price: $1.42 info
Change: +$0.210 (+17%) info
Market Cap: $265.039M info
INO
Nov 05, 2026, 11:19 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1.23
Real-time Price: $1.42 info
Change: +$0.1906 (+16%) info
Market Cap: $265.039M info